.jpg?format=webp&quality=80&width=3840)
The article discusses the use of heterobifunctional protein degraders, specifically PROTAC protein degraders, as a novel therapeutic approach for selectively targeting disease-related proteins for degradation using the cell's natural protein-degradation machinery. Protein degraders offer several advantages over traditional small-molecule inhibitors for cancer treatment, including their ability to target multiple copies of a protein of interest and previously "undruggable" proteins. Currently, 18 protein degraders are in clinical trials for various tumor types, and early results show promising activity as cancer therapies. The article reviews protein degrader development, preclinical research, available data in patients, and future directions for this new class of drugs.
Like
Save
Share